Bionxt to acquire IP to sublingual drug formulation

Executive Summary

• Bionxt Solutions Inc. signed a letter agreement to acquire 100 % of the IP rights for a novel sublingual drug formulation targeting oncology and immunosuppressant therapies.
• The co‑developer will receive a 20 % royalty on licence fees paid to Bionxt, capped at US$50 million in aggregate payments.
• Both parties aim to finalize a definitive IP and collaboration agreement within the next 60 days, with provisional patent filings expected by year‑end.

Key Details

• Agreement Scope: Exclusive rights to a high‑potency sublingual formulation for chemotherapy and immunosuppressant treatments.
• Royalty Structure: Co‑developer entitled to 20 % of licence fees received by Bionxt from third‑party licensees, with an aggregate cap of US$50 million.
• Timeline: Definitive IP and collaboration agreement targeted for execution within 60 days of the letter agreement; provisional patent filings planned before year‑end.
• Strategic Fit: Complements Bionxt’s lead program—a sublingual thin‑film cladribine formulation for multiple sclerosis—expanding its IP portfolio and product pipeline.
• Market Context: Global immunosuppressant market projected to reach US$61.05 billion by 2025 (Statista), underscoring commercial potential.

Notable Quotes

“This chemotherapy and immunosuppressant product opportunity is an excellent complement to our lead development program… We expect to file provisional patents for our new sublingual product by year‑end, which will expand our growing intellectual property portfolio and product pipeline.” – Hugh Rogers, CEO, Bionxt Solutions.